Planning and sourcing new products and strengthening original products
First written in FY2016. 17 of 27 entries say "Advanced", first in FY2017. Latest entry: 2026-10-17.
19 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「For original products, the company sought to strengthen its product lineup and promotional activities by introducing dual-brand OEM products made with well-known manufacturers, among other measures. Sales rose to ¥35.721 billion, up 6.8% year on year.」
Sales of original products were ¥35.721 billion, up 6.8% year on year, as the company proceeded with the introduction of dual-brand OEM products. - FY2026-H1AdvancedAnnual report
「For original products, the company strengthened its product lineup and promotional activities by introducing dual-brand OEM products made with well-known manufacturers, among other measures. Sales rose to ¥16.677 billion, up 4.7% year on year, with growth exceeding that of the previous interim period.」
Sales of original products were ¥16.677 billion, up 4.7% year on year. The company strengthened its product lineup and promotional activities by introducing dual-brand OEM products made with leading manufacturers, among other measures. - FY2025AdvancedAnnual report
「Sales of original products have now reached ¥33.4 billion, and the company aims to increase this to 1.3 times that level, or ¥42.0 billion, in 3 years. In addition to proprietary development, the company will accelerate the rollout of private-label products by expanding dual-brand products developed in collaboration with leading manufacturers and OEM products.」
The company reported sales of original products of ¥33.4 billion and set a target of ¥42.0 billion in 3 years, outlining a policy of expanding proprietary development, dual-brand products and OEM products. - FY2022-Q3AdvancedAnnual report
「Changes in behavior associated with the COVID-19 pandemic have driven demand for e-commerce-related services that contribute to DX, particularly centralized purchasing. In addition, the number of products handled online exceeded 5.8 million, and the expansion of new product offerings contributed to sales.」
The expansion of products handled online and the expansion of new merchandise were cited as factors contributing to sales. - FY2022-Q1RestatedAnnual report
「During the cumulative consolidated first quarter, ¥4 million was recorded for research and development activities, focused mainly on developing new products. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated first quarter.」
The company continued research and development activities focused on developing new products and recorded ¥4 million. It stated that there were no material changes in the status of its research and development activities. - FY2021-Q3RestatedAnnual report
「During the cumulative consolidated third quarter, ¥20 million was recorded for research and development activities, focused mainly on developing new products. There were no material changes in the status of the Group's research and development activities during the cumulative consolidated third quarter.」
The company continued research and development activities focused on developing new products and recorded ¥20 million. It stated that there were no material changes in the status of these activities. - FY2020AdvancedAnnual report
「Products for nursing care facilities, MRO supplies for factories, and services such as rental and equipment calibration, which the company is pursuing as new products, grew.」
Products for nursing care facilities and MRO supplies for factories grew, along with rental and equipment calibration services, contributing to the results of the growth strategy. - FY2020-Q3AdvancedAnnual report
「The factors included continued growth in e-commerce-style centralized purchasing and sales to online retailers, contributions from sales of web-only products, whose range had expanded to more than 4 million items, to acquiring new sales, and growth in new products such as products for nursing care facilities, MRO supplies for factories, rental services and calibration services.」
New products such as products for nursing care facilities, MRO supplies for factories, rental services and calibration services grew. - FY2020-Q2AdvancedAnnual report
「Growth in new products, including products for nursing care facilities and MRO supplies for factories, contributed to the increase.」
New products, including products for nursing care facilities and MRO supplies for factories, grew, and cumulative second-quarter sales totaled ¥1.714 billion, representing 131.1% of the same quarter of the previous year. - FY2020-Q1RestatedAnnual report
「During the current first quarter cumulative consolidated period, ¥7 million was recorded for research and development activities, primarily focused on developing new products.」
The company continued research and development activities centered on new product development and recorded ¥7 million during the current first quarter. No new milestones, such as completion or launch of new products, were disclosed. - FY2019AdvancedAnnual report
「The new products undertaken as a new area through PROJECT -NANA- include original medical devices, MRO products for production sites and reagents, as well as initiatives to strengthen sales and services for researchers, and continue to grow.」
Full-year sales of new products totaled ¥2.997 billion, up 40.2% year on year, with services for researchers strengthened in addition to product sales. - FY2019-Q3AdvancedAnnual report
「In the research and industrial equipment divisions, we published a comprehensive research catalog in November 2018 and revamped it into a catalog with an unparalleled range of products, featuring more than 3,300 pages and approximately 75,000 listed items, approximately 1.5 times the previous level, including a large number of new products.」
The company published a comprehensive research catalog featuring a large number of new products, concretely expanding its range of new products. - FY2019-Q2AdvancedAnnual report
「New products 822 1,307 158.9 102.0」
Cumulative second-quarter sales of new products under the medium-term management plan totaled ¥1.307 billion, representing 158.9% of the same quarter of the previous year and 102.0% of the plan for the same period. - FY2019-Q1AdvancedAnnual report
「New products 390 599 153.7 95.8」
Sales of new products under the medium-term management plan totaled ¥599 million, representing 153.7% of the same quarter of the previous year and 95.8% of the plan for the same period. - FY2018AdvancedAnnual report
「As new products undertaken through Project -NANA-, the company is strengthening sales of original medical devices, MRO products for production sites and reagents, as well as services for researchers.」
The company is strengthening sales of original medical devices, MRO products for production sites and reagents, in addition to services for researchers. - FY2018-Q3RestatedAnnual report
「During the current third quarter cumulative consolidated period, ¥16 million was recorded for research and development activities, primarily focused on developing new products. There were no material changes in the status of the Group's research and development activities during the current third quarter cumulative consolidated period.」
The company continued research and development activities centered on new product development and recorded ¥16 million. - FY2018-Q2RestatedAnnual report
「During the current second quarter cumulative consolidated period, ¥12 million was recorded for research and development activities, primarily focused on developing new products. There were no material changes in the status of the Group's research and development activities during the current second quarter cumulative consolidated period.」
The company continued research and development activities centered on new product development and recorded ¥12 million. No new milestones, such as completion or launch of new products, were disclosed. - FY2018-Q1RestatedAnnual report
「During the current first quarter cumulative consolidated period, ¥8 million was recorded for research and development activities, primarily focused on developing new products.」
The company continued research and development activities centered on new product development and recorded ¥8 million during the quarter. No new milestones, such as completion or launch of new products, were disclosed. - FY2017AdvancedAnnual report
「Among the new products undertaken through Project -NANA-, several have begun to emerge, including original medical devices, MRO products for production sites, and reagents. The company will develop these into larger businesses while exploring additional product fields requiring deeper development.」
The company stated that original medical devices, MRO products for production sites and reagents had begun to emerge as new products. - FY2017-Q3RestatedAnnual report
「During the current third quarter cumulative consolidated period, ¥36 million was recorded for research and development activities, primarily focused on developing new products.」
The company continued research and development activities centered on new product development and recorded ¥36 million during the current third quarter cumulative consolidated period. - FY2017-Q2RestatedAnnual report
「During the current second quarter cumulative consolidated period, ¥34 million was recorded for research and development activities, primarily focused on developing new products.」
The company continued research and development activities centered on new product development and recorded ¥34 million during the cumulative quarter. - FY2017-Q1RestatedAnnual report
「During the current first quarter cumulative consolidated period, ¥13 million was recorded for research and development activities, primarily focused on developing new products.」
The company continued research and development activities centered on new product development and recorded ¥13 million during the quarter. - FY2016First statedAnnual report
「The Group has pursued differentiation from competitors by improving the range, quality and functionality of catalog products, setting competitive prices, and developing original products.」
The company positions product range, quality, functionality, pricing and original product development as means of differentiation.